Blood glucose testing and primary prevention of diabetes mellitus type 2 - evaluation of the effect of evidence based patient information

<p>Abstract</p> <p>Background</p> <p>Evidence-based patient information (EBPI) has been recognised as important tool for informed choice in particular in the matter of preventive options. An objective, on the best scientific evidence-based consumer information about subthreshold elevated blood glucose levels (impaired fasting glucose and impaired glucose tolerance) and primary prevention of diabetes, is not available yet. Thus we developed a web-based EBPI and aim to evaluate its effects on informed decision making in people 50 years or older.</p> <p>Methods/Design</p> <p>We conduct a web-based randomised-controlled trial to evaluate the effect of information about elevated blood glucose levels and diabetes primary prevention on five specific outcomes: (i) knowledge of elevated blood glucose level-related issues (primary outcome); (ii) attitudes to a metabolic testing; (iii) intention to undergo a metabolic testing; (iv) decision conflict; (v) satisfaction with the information. The intervention group receives a specially developed EBPI about subthreshold elevated blood glucose levels and diabetes primary prevention, the control group information about this topic, available in the internet.</p> <p>The study population consists of people between 50 and 69 years of age without known diabetes. Participants will be recruited via the internet page of the cooperating health insurance company, Techniker Krankenkasse (TK), and the internet page of the German Diabetes Centre. Outcomes will be measured through online questionnaires. We expect better informed participants in the intervention group.</p> <p>Discussion</p> <p>The design of this study may be a prototype for other web-based prevention information and their evaluation.</p> <p>Trial registration</p> <p>Current Controlled Trial: ISRCTN22060616.</p

Drivers of the cost of capital: The joint role of non-financial metrics

Recent marketing studies suggest that non-financial metrics, such as customer satisfaction and brand value, help explain the variation in the cost of equity and the cost of debt. These studies typically focus on only one non-financial metric and one component of capital cost. In this study, we broaden the understanding of the relevance of non-financial metrics to the cost of capital. We investigate the joint role of customer satisfaction, brand value, and corporate reputation for stock market beta and credit ratings, which reflect variation in equity and debt risk premiums across firms. In addition to the joint direct influence of these metrics on capital cost, we also study their interaction effects. We develop a conceptual model to explain the effects on capital costs and test the resulting hypotheses in a broad sample of 344 firms from diverse industries using data from the 1991-2006 period.Our results suggest that higher satisfaction ratings reduce both the cost of equity and cost of debt, whereas brand value and corporate reputation only show a negative direct association with the cost of debt. In addition, both measures moderate the effect of satisfaction on the cost of debt. Brand value attenuates the influence of satisfaction, whereas corporate reputation amplifies this effect. © 2013 Elsevier B.V

Formation and Persistence of Metabolites of Imazamethabenz-methyl in a Sandy Loam Soil

The fate of imazamethabenz-methy1 was studied in a sandy loam soil after application in spring to winter wheat (Triticum aestivum L.). Imazamethabenz-methyl and its metabolite 2 (2-(4, 5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-H-1-imidazol-2-yl)4-methylbenzoic acid, in mixture with the 5-methylbenzoic acid isomer) were further transformed into the metabolites 3 (2-(4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-H-1-imidazol-2-yl)-1,4-benzenedicarboxylic acid, in mixture with the 1,5-benzenedicarboxylic acid isomer), and 4 (1,2,4-benzenetricarboxylic acid, in mixture with the 1,2,5-isomer). Meta-bolites 3 and 4 reached maximum concentration levels in the 0-13 cm layer corresponding to 14-17% and 9-14% of the imazamethabenz-methy1 dose, respectively. These maxima were reached be tween 105 and 177 days after application. Imazamethabenz-methyl metabolism was slower in plots treated with organic fertilizers than in untreated plots. After 196 days the concentrations of all metabolites in the 0-13 cm layer had declined to, at most, 0.01 mg kg(-1). There was no carry-over of residues that could be phytotoxic to the next crop